Study summary · research use only
Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This narrative review examines the use of oral, topical, and intravenous glutathione, a tripeptide with antioxidant and melanogenesis-regulating properties, for skin lightening in humans. The abstract reports that oral administration was associated with significant but variable decreases in melanin levels with limited side effects, topical formulations were associated with melanin reduction and improved skin texture with varying sustainability, and intravenous glutathione acted rapidly but was associated with safety concerns including anaphylaxis and hepatotoxicity, compounded by a lack of standardized dosing protocols. The review states that current evidence supports glutathione's potential as a depigmenting agent but calls for large-scale clinical trials to establish long-term outcomes, optimal dosing, and standardized use, particularly for intravenous administration.
Abstract
The rising demand for skin-lightening products has brought glutathione, a tripeptide with antioxidant properties and melanogenesis-regulating effects, into focus as a potentially safer alternative to conventional agents. This narrative review aims to evaluate the efficacy and safety of oral, topical, and intravenous glutathione in skin-lightening therapies. Oral administration shows significant but variable decreases in melanin levels with limited side effects. Topical formulations provide good-level melanin reduction and skin texture improvement but with varying sustainability. Intravenous glutathione, although having rapid action, is associated with serious safety concerns like anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols. Current evidence supports glutathione's potential as a depigmenting agent but underscores the need for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. Until such data are available, clinicians and consumers should exercise caution to ensure safe and effective dermatological practices, particularly with intravenous use.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.